|
US4234571A
(en)
*
|
1979-06-11 |
1980-11-18 |
Syntex (U.S.A.) Inc. |
Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
|
|
DE3411224A1
(de)
*
|
1984-03-27 |
1985-10-10 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren
|
|
US4760053A
(en)
*
|
1984-08-02 |
1988-07-26 |
Fernand Labrie |
Combination therapy for selected sex steroid dependent cancers
|
|
US4666885A
(en)
*
|
1985-02-08 |
1987-05-19 |
Fernand Labrie |
Combination therapy for treatment of female breast cancer
|
|
US4705778A
(en)
*
|
1985-10-22 |
1987-11-10 |
Sri International |
Orally active LHRH analogs
|
|
JPH0284272U
(nl)
*
|
1988-12-20 |
1990-06-29 |
|
|
|
JP2672677B2
(ja)
*
|
1989-02-09 |
1997-11-05 |
タツプ・フアーマシユーテイカルズ・インコーポレイテツド |
Ｌｈｒｈ同族体
|
|
DK0462189T3
(da)
*
|
1989-03-10 |
1995-11-20 |
Endorecherche Inc |
Kombinationsterapi til behandling af østrogenfølsomme sygdomme
|
|
US5372996A
(en)
*
|
1989-03-10 |
1994-12-13 |
Endorecherche, Inc. |
Method of treatment of androgen-related diseases
|
|
AU5856090A
(en)
*
|
1989-07-07 |
1991-02-06 |
Endorecherche Inc. |
Androgen derivatives for use in the inhibition of sex steroid activity
|
|
DE69034035T2
(de)
*
|
1989-07-07 |
2004-01-22 |
Endorecherche Inc., Ste-Foy |
Methode zur behandlung androgenbedingter krankheiten
|
|
GB9112859D0
(en)
*
|
1991-06-14 |
1991-07-31 |
Ici Plc |
Peptide process
|
|
AU4258493A
(en)
*
|
1992-05-21 |
1993-12-13 |
Endorecherche Inc. |
Inhibitors of testosterone 5alpha-reductase activity
|
|
US7833543B2
(en)
*
|
1995-06-07 |
2010-11-16 |
Durect Corporation |
High viscosity liquid controlled delivery system and medical or surgical device
|
|
US6413536B1
(en)
|
1995-06-07 |
2002-07-02 |
Southern Biosystems, Inc. |
High viscosity liquid controlled delivery system and medical or surgical device
|
|
CA2192782C
(en)
|
1995-12-15 |
2008-10-14 |
Nobuyuki Takechi |
Production of microspheres
|
|
CA2192773C
(en)
|
1995-12-15 |
2008-09-23 |
Hiroaki Okada |
Production of sustained-release preparation for injection
|
|
WO1999007874A1
(fr)
*
|
1996-06-13 |
1999-02-18 |
Itoham Foods Inc. |
Procede de production de derives de lh-rh
|
|
US20060025328A1
(en)
*
|
1997-05-28 |
2006-02-02 |
Burns Patrick J |
Compositions suitable for controlled release of the hormone GnRH and its analogs
|
|
US6051558A
(en)
*
|
1997-05-28 |
2000-04-18 |
Southern Biosystems, Inc. |
Compositions suitable for controlled release of the hormone GnRH and its analogs
|
|
US6242421B1
(en)
|
1997-11-06 |
2001-06-05 |
Richard Lloyd Bowen |
Methods for preventing and treating Alzheimer's disease
|
|
US6858598B1
(en)
|
1998-12-23 |
2005-02-22 |
G. D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
US6833373B1
(en)
|
1998-12-23 |
2004-12-21 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
US20040258672A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Graft acceptance through manipulation of thymic regeneration
|
|
AUPR074500A0
(en)
*
|
2000-10-13 |
2000-11-09 |
Monash University |
Treatment of t cell disorders
|
|
US20070274946A1
(en)
*
|
1999-04-15 |
2007-11-29 |
Norwood Immunoloty, Ltd. |
Tolerance to Graft Prior to Thymic Reactivation
|
|
US20040265285A1
(en)
*
|
1999-04-15 |
2004-12-30 |
Monash University |
Normalization of defective T cell responsiveness through manipulation of thymic regeneration
|
|
US20040241842A1
(en)
*
|
1999-04-15 |
2004-12-02 |
Monash University |
Stimulation of thymus for vaccination development
|
|
US20040259803A1
(en)
*
|
1999-04-15 |
2004-12-23 |
Monash University |
Disease prevention by reactivation of the thymus
|
|
US20050020524A1
(en)
*
|
1999-04-15 |
2005-01-27 |
Monash University |
Hematopoietic stem cell gene therapy
|
|
ES2154590B1
(es)
|
1999-05-20 |
2001-11-01 |
Lipotec Sa |
Procedimiento de sintesis de peptidos en fase solida
|
|
AR023940A1
(es)
|
2000-05-03 |
2002-09-04 |
Eriochem Sa |
Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
|
|
DE10032256C2
(de)
*
|
2000-07-03 |
2003-06-05 |
Infineon Technologies Ag |
Chip-ID-Register-Anordnung
|
|
US20060088512A1
(en)
*
|
2001-10-15 |
2006-04-27 |
Monash University |
Treatment of T cell disorders
|
|
ES2629317T3
(es)
|
2001-02-19 |
2017-08-08 |
Novartis Ag |
Tratamiento de tumores cerebrales sólidos con un derivado de rapamicina
|
|
HUP0400038A3
(en)
|
2001-05-16 |
2007-05-29 |
Novartis Ag |
Combination comprising n-{5-[4-{-methyl-piperazino-methyl)-benzoylamino]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
|
|
US20060287282A1
(en)
*
|
2001-06-25 |
2006-12-21 |
Steiner Mitchell S |
Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
|
|
CA2466659A1
(en)
|
2001-11-13 |
2003-05-22 |
Takeda Chemical Industries, Ltd. |
Anticancer agents
|
|
GB0128510D0
(en)
*
|
2001-11-28 |
2002-01-23 |
Novartis Ag |
Organic compounds
|
|
US20030144203A1
(en)
*
|
2001-12-19 |
2003-07-31 |
Voyager Pharmaceutical Corporation |
Methods for slowing senescence and treating and preventing diseases associated with senescence
|
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
|
SI1505959T1
(sl)
|
2002-05-16 |
2009-04-30 |
Novartis Ag |
Uporaba vezavnih sredstev EDG receptorjev pri raku
|
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
|
DK1575569T3
(da)
|
2002-12-13 |
2011-01-10 |
Durect Corp |
Oralt indgivelsessystem omfattende flydende bærematerialer med høj viskositet
|
|
PL2256106T3
(pl)
|
2003-07-22 |
2015-08-31 |
Astex Therapeutics Ltd |
Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
|
|
GB0320806D0
(en)
*
|
2003-09-05 |
2003-10-08 |
Astrazeneca Ab |
Therapeutic treatment
|
|
US20080279812A1
(en)
*
|
2003-12-05 |
2008-11-13 |
Norwood Immunology, Ltd. |
Disease Prevention and Vaccination Prior to Thymic Reactivation
|
|
ES2396195T3
(es)
|
2004-04-07 |
2013-02-19 |
Novartis Ag |
Inhibidores de IAP
|
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
|
EP1758932A2
(en)
*
|
2004-06-25 |
2007-03-07 |
Takeda Pharmaceutical Company Limited |
Metastin derivatives and use thereof
|
|
SI2415484T1
(sl)
|
2004-09-17 |
2014-10-30 |
Durect Corporation |
Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
|
|
GB0425854D0
(en)
*
|
2004-11-25 |
2004-12-29 |
Astrazeneca Ab |
Therapeutic treatment
|
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
|
ES2552338T3
(es)
|
2005-01-21 |
2015-11-27 |
Astex Therapeutics Limited |
Compuestos farmacéuticos
|
|
EP2119725A1
(en)
|
2005-05-03 |
2009-11-18 |
Novetide Ltd. |
Methods for the production of leuprolide
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
|
US20080255149A1
(en)
|
2005-09-27 |
2008-10-16 |
Novartis Ag |
Carboxyamine Compounds and Methods of Use Thereof
|
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
|
KR20090007635A
(ko)
|
2006-05-09 |
2009-01-19 |
노파르티스 아게 |
철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도
|
|
RU2009115954A
(ru)
|
2006-09-29 |
2010-11-10 |
Новартис АГ (CH) |
Пиразолопиримидины в качестве ингибиторов липидной киназы р13к
|
|
JP5528806B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
CA2677750A1
(en)
|
2006-11-03 |
2008-06-05 |
Durect Corporation |
Transdermal delivery systems
|
|
AR065335A1
(es)
|
2007-02-15 |
2009-06-03 |
Novartis Ag |
Combinaciones de agentes terapeuticos para el tratamiento de cancer
|
|
AU2008347158B8
(en)
*
|
2007-12-06 |
2013-08-22 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
|
AU2009228765B2
(en)
|
2008-03-24 |
2012-05-31 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
|
CA2719477C
(en)
|
2008-03-26 |
2016-11-08 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases b
|
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
|
CA2744937C
(en)
*
|
2008-11-28 |
2017-02-28 |
Novartis Ag |
Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
|
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
|
TW201031406A
(en)
|
2009-01-29 |
2010-09-01 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
|
ES2475945T3
(es)
|
2009-06-26 |
2014-07-11 |
Novartis Ag |
Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
CA2770873A1
(en)
|
2009-08-12 |
2011-02-17 |
Novartis Ag |
Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
|
|
KR20120089463A
(ko)
|
2009-08-20 |
2012-08-10 |
노파르티스 아게 |
헤테로시클릭 옥심 화합물
|
|
US20120149661A1
(en)
|
2009-08-26 |
2012-06-14 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
|
MX2012002997A
(es)
|
2009-09-10 |
2012-08-01 |
Novartis Ag |
Derivados de eter de los heteroarilos biciclicos.
|
|
PE20121471A1
(es)
|
2009-11-04 |
2012-11-01 |
Novartis Ag |
Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
|
|
CN102712648A
(zh)
|
2009-11-25 |
2012-10-03 |
诺瓦提斯公司 |
双环杂芳基的与苯稠合的6元含氧杂环衍生物
|
|
WO2011070030A1
(en)
|
2009-12-08 |
2011-06-16 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
|
KR20150039882A
(ko)
|
2010-06-16 |
2015-04-13 |
앙도르쉐르슈 인코포레이티드 |
에스트로겐-관련 질병의 치료 또는 예방 방법
|
|
JP2013532149A
(ja)
|
2010-06-17 |
2013-08-15 |
ノバルティス アーゲー |
ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
|
|
JP2013528635A
(ja)
|
2010-06-17 |
2013-07-11 |
ノバルティス アーゲー |
ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
|
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
|
JP2013537210A
(ja)
|
2010-09-16 |
2013-09-30 |
ノバルティス アーゲー |
１７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
|
|
JP2014505088A
(ja)
|
2011-02-10 |
2014-02-27 |
ノバルティス アーゲー |
Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
|
|
JP2014507465A
(ja)
|
2011-03-08 |
2014-03-27 |
ノバルティス アーゲー |
フルオロフェニル二環式ヘテロアリール化合物
|
|
JP6002210B2
(ja)
|
2011-04-28 |
2016-10-05 |
ノバルティス アーゲー |
１７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
|
|
MX365242B
(es)
|
2011-05-16 |
2019-05-28 |
Genzyme Corp |
El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
|
|
CA2838029A1
(en)
|
2011-06-09 |
2012-12-13 |
Novartis Ag |
Heterocyclic sulfonamide derivatives
|
|
EP2721008B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
|
|
EP2721007B1
(en)
|
2011-06-20 |
2015-04-29 |
Novartis AG |
Cyclohexyl isoquinolinone compounds
|
|
EP2723740A1
(en)
|
2011-06-27 |
2014-04-30 |
Novartis AG |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
|
CA2848809A1
(en)
|
2011-09-15 |
2013-03-21 |
Novartis Ag |
6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
|
|
JP5992054B2
(ja)
|
2011-11-29 |
2016-09-14 |
ノバルティス アーゲー |
ピラゾロピロリジン化合物
|
|
JP5903499B2
(ja)
|
2011-12-22 |
2016-04-13 |
ノバルティス アーゲー |
ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体
|
|
WO2013093850A1
(en)
|
2011-12-22 |
2013-06-27 |
Novartis Ag |
Quinoline derivatives
|
|
KR20140107578A
(ko)
|
2011-12-23 |
2014-09-04 |
노파르티스 아게 |
Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
|
|
US20140357666A1
(en)
|
2011-12-23 |
2014-12-04 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
MX2014007729A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
|
WO2013096059A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
BR112014015339A8
(pt)
|
2011-12-23 |
2017-06-13 |
Novartis Ag |
compostos para inibição da interação de bcl2 com parceiros de ligação
|
|
UY34591A
(es)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
Compuestos de imidazopirrolidinona
|
|
UY34807A
(es)
|
2012-05-16 |
2013-12-31 |
Novartis Ag |
Derivados monocíclicos de heteroarilcicloalquil- diamina
|
|
CN104321325B
(zh)
|
2012-05-24 |
2016-11-16 |
诺华股份有限公司 |
吡咯并吡咯烷酮化合物
|
|
EP2861256B1
(en)
|
2012-06-15 |
2019-10-23 |
The Brigham and Women's Hospital, Inc. |
Compositions for treating cancer and methods for making the same
|
|
MX2015002006A
(es)
|
2012-08-13 |
2015-06-02 |
Novartis Ag |
Derivados de heteroaril-cicloalquildiamina biciclicos como inhibidores de tirosina cinasas del bazo (syk).
|
|
CN107434803B
(zh)
|
2012-10-02 |
2020-05-05 |
吉利德科学公司 |
组蛋白去甲基化酶抑制剂
|
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫－吡啶并－□衍生物之固體形式
|
|
US9403827B2
(en)
|
2013-01-22 |
2016-08-02 |
Novartis Ag |
Substituted purinone compounds
|
|
WO2014115080A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
|
KR102229992B1
(ko)
|
2013-02-27 |
2021-03-19 |
에피테라퓨틱스 에이피에스 |
히스톤 데메틸라아제의 저해제
|
|
TW201521769A
(zh)
|
2013-03-15 |
2015-06-16 |
Durect Corp |
具有流變改質劑以減少溶解變異性之組成物
|
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
|
US9670194B2
(en)
|
2013-09-22 |
2017-06-06 |
Calitor Sciences, Llc |
Substituted aminopyrimidine compounds and methods of use
|
|
CN105916515A
(zh)
|
2014-01-15 |
2016-08-31 |
诺华股份有限公司 |
药物组合
|
|
EP3122728A4
(en)
|
2014-03-28 |
2017-10-25 |
Calitor Sciences, LLC |
Substituted heteroaryl compounds and methods of use
|
|
JP2017512804A
(ja)
|
2014-03-31 |
2017-05-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ヒストン脱メチル化酵素の阻害剤
|
|
MX2016012893A
(es)
|
2014-04-03 |
2017-05-12 |
Invictus Oncology Pvt Ltd |
Sustancias terapéuticas combinadas supramoleculares.
|
|
JP2017526675A
(ja)
|
2014-08-27 |
2017-09-14 |
ギリアード サイエンシーズ， インコーポレイテッド |
ヒストンデメチラーゼを阻害するための化合物および方法
|
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
|
EP3710006A4
(en)
|
2017-11-19 |
2021-09-01 |
Sunshine Lake Pharma Co., Ltd. |
SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
|
|
AU2017444054B2
(en)
|
2017-12-21 |
2021-10-07 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
|
WO2019143874A1
(en)
|
2018-01-20 |
2019-07-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
|
US20220401336A1
(en)
*
|
2019-09-26 |
2022-12-22 |
S.I.S. Shulov Innovative Science Ltd. |
Anti-aging compositions and methods of use thereof
|
|
EP4058465A1
(en)
|
2019-11-14 |
2022-09-21 |
Cohbar Inc. |
Cxcr4 antagonist peptides
|
|
BR112022013784A2
(pt)
|
2020-01-13 |
2022-10-11 |
Durect Corp |
Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados
|